ClinicalTrials.gg
RecruitingNCT07248904Updated Mar 27, 2026

The Effect of a Transtheoretical Model-Based Educational Intervention on First-Year Nursing Students' HPV Knowledge, Health Beliefs, and Vaccination Behavior Intentions

An interventional study of TTM-Based Educational Program in Human Papillomavirus (HPV), Papillomavirus Vaccines and Health Knowledge, Attitudes, Practice, sponsored by Cukurova University. Recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Primary conditionHealth BehaviorRegistry: BehaviorReclassifiedWhy we changed it
Registry
Behavior — the first condition term the registry derived for this study.
ClinicalTrials.gg
Health Behavior
Why
  1. The study's listed conditions name Health Behavior, a narrower term within Behavior.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Cukurova University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Health Behavior with a site in Turkey — 15 open to participants now, 17 under way, none of them phase 3. Health Behavior · Turkey.

Planned enrollment
26th of 62
88 · median 79
Started
2026
with 5 others
No phase
62 of 73
12 open now
Primary completion
2026-03
later than 10 of 16 live
Registered
59th of 73
by date

Among the 73 studies in Health Behavior with a site in Turkey, this one is the 26th largest by planned enrollment of the 62 interventional ones that give a count, is one of 6 that started in 2026, is one of 62 with no phase, reaches primary completion later than 10 of the 16 other live ones, and was the 59th registered.

Health Behavior

970 studies on the registry are indexed under Health Behavior; 166 are open to participants now.

Browse Health Behavior studies →

Open to participants now

15 of the 73 studies in Health Behavior with a site in Turkey are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 94 Health Behavior studies recruiting now, 39 (41%) set no upper age limit and 38 (40%) stop at 75 or younger; 25 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Health Behavior with a site in Turkey, or all of them as a file.
02

Study summary

The purpose of this study is to examine the impact of a structured educational program based on the Transtheoretical Model (TTM) on HPV knowledge, health beliefs, and vaccination behavioral intentions among first-year nursing students. The study will also evaluate how the intervention affects students' HPV vaccine readiness compared to the TTM.

The primary questions addressed by the study are:

  • Does the TTM-based educational intervention increase students' knowledge about HPV and the HPV vaccine?
  • Does the program change students' health beliefs regarding susceptibility, severity, benefits, and barriers to HPV and the HPV vaccine?
  • Does the program improve students' intentions and readiness to receive the HPV vaccine?
  • Do students move to a higher behavioral readiness stage (from Precontemplation to Contemplation, Preparation, Action, or Maintenance) after the intervention?

The researcher will compare the TTM-based educational intervention with a control group that did not receive structured education to determine whether a personalized, stage-based approach is more effective in improving HPV-related outcomes among nursing students.

Participants will:

  • Complete baseline questionnaires measuring HPV knowledge, health beliefs, and vaccination intention.
  • The experimental group (intervention group) will receive personalized TTM-based education, face-to-face instruction in modules aligned with the five TTM phases (Precontemplation, Contemplation, Preparation, Action, and Maintenance).
  • The experimental group will participate in educational sessions designed to raise awareness, correct misinformation, support decision-making, and encourage protective behaviors.
  • The control group will not receive any educational program.
  • All participants in the experimental and control groups will complete the same questionnaires again to assess changes after the intervention.

The TTM-based educational intervention provides:

  • Staged counseling
  • Information about HPV and the HPV vaccine
  • Activities to raise awareness, strengthen motivation, and support vaccination adoption
  • Personalized feedback based on student readiness
  • Structured modules focusing on knowledge, belief, and behavior change strategies

The study population included first-year nursing students enrolled in the Faculty of Health Sciences. A total of 88 participants will be recruited and randomly assigned to either the intervention (n=44) or control (n=44) groups through simple randomization.

The results of this study are expected to contribute to the development of evidence-based education strategies in nursing, support of behavioral change models in health education, and strengthen the role of future nurses in HPV prevention, vaccine advocacy, and public health practice.

03

Conditions studied

  • Human Papillomavirus (HPV)
  • Papillomavirus Vaccines
  • Health Knowledge, Attitudes, Practice
  • Students, Nursing
  • Health Behavior

Browse trials for

04

In context

Health Behavior Reclassified

970 studies on the registry are indexed under Health Behavior; 166 are open to participants now.

This study's planned enrollment of 88 is below the median of 150 across 826 interventional studies indexed under Health Behavior.

Browse Health Behavior studies →

Lead sponsor

Cukurova University is the lead sponsor of 261 studies on the registry; 48 are open to participants now.

Compared within Health Behavior, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Behavior. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First-year students enrolled in the Nursing Department of the Faculty of Health Sciences
  • Provide written to participate
  • Agree to attend all educational sessions and data collection appointments during the study period
  • Have sufficient Turkish literacy to read and understand study materials
  • Have not previously received any comprehensive education about HPV infection or HPV vaccination

Exclusion criteria

Exclusion Criteria:

  • Students who do not agree to participate in the study
  • Students who do not provide written
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    TTM-based structured educational program tailored to the participant's stage of readiness for HPV vaccination

    Behavioral: TTM-Based Educational Program

  • No intervention
    Control Group

    No structured education; participants receive no TTM-based training during the study period.

Interventions

  • BehavioralTTM-Based Educational Program

    A structured, stage-matched educational intervention based on the Transtheoretical Model, delivered face-to-face in five modules aligned with Precontemplation, Contemplation, Preparation, Action, and Maintenance stage

07

What researchers measure

Primary outcomes

  1. Vaccination Behavior Intention Scale

    Behavioral intention to receive the HPV vaccine will be assessed using the HPV Vaccination Intention Scale, a 6-item instrument developed based on the Theory of Planned Behavior. The scale evaluates participants' intention to receive the HPV vaccine, with higher scores indicating stronger intention to be vaccinated. The secondary outcome is the change in intention score from baseline to post-intervention.

    Time frame: Baseline and after completion of the 10-week intervention (5 sessions delivered every 2 weeks)

Secondary outcomes

  1. HPV Knowledge Scale

    HPV knowledge will be measured using the HPV Knowledge Scale (HPV-BS), a validated 33-item instrument consisting of four subscales: general HPV knowledge (16 items), HPV screening knowledge (6 items), HPV vaccine knowledge (5 items), and HPV vaccination program knowledge (6 items). Total scores range from 0 to 35, with higher scores indicating greater knowledge about HPV infection, transmission, screening, and vaccination. A Cronbach's alpha coefficient of 0.96 was reported in the Turkish validity and reliability study. The primary outcome is the change in total HPV knowledge score from baseline to postintervention.

    Time frame: Baseline and after completion of the 10-week intervention (5 sessions delivered every 2 weeks)

  2. Health Belief Model Scale regarding HPV and vaccination

    Health beliefs regarding HPV and HPV vaccination will be measured using the Health Belief Model Scale (HBM-HPV), a validated instrument developed by Kim (2016) and adapted into Turkish by Guvenc et al. (2016). The scale consists of four subscales: perceived benefits (items 1-3), perceived susceptibility (items 4-5), perceived severity (items 6-9), and perceived barriers (items 10-13 and 15). Higher scores indicate stronger beliefs within each construct. Except for perceived barriers, all subscales are positively associated with HPV vaccination intention. Cronbach's alpha values for the subscales range from 0.71 to 0.78. The secondary outcome is the change in subscale scores from baseline to post-intervention.

    Time frame: Baseline and after completion of the 10-week intervention (5 sessions delivered every 2 weeks)

08

Study locations

1 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because the study involves identifiable student information, and sharing raw data may pose confidentiality and privacy risks. Data will be stored securely and used only for the purposes approved by the ethics committee. Only aggregated and de-identified results will be reported in publications.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2026, 2 months after the start.

Of 569 non-industry interventional studies with no phase under Health Behavior, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 33. This study's planned 2 months is below that.

Counting every sponsor, half of 587 studies reached it within 15 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 25, 2025
StartActual
Jan 16, 2026
Primary completionEst.
Mar 30, 2026
CompletionEst.
Apr 30, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07248904
Responsible party
MÜJDE KERKEZ (Asist. Prof. Dr., Cukurova University) — Principal investigator
First posted
Nov 25, 2025
Start date
Jan 16, 2026
Primary completion
Mar 30, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

MÜJDE KERKEZ, Asist. Prof. Dr
Contact
mujjde_@hotmail.com
+905059718697

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion